GuideStart with the ingredient before you compare the offer.
GuideCompare the service and commitment behind injections and infusions.
GuideHow to compare quantities, billing cycles and required fees.
GuideA closer look at the prescription, pharmacy and actual formulation.
GuideA few distinctions that make longevity marketing easier to evaluate.
ResearchRead the ingredient, population and endpoint before interpreting a longevity claim.
ResearchHow to read percentages, blood tests and claims about feeling better.
ResearchA practical distinction between ingredient evidence, administration and compounded-product quality.
ResearchAn 11-person pilot mapped NAD metabolites over eight hours. Here is what it can—and cannot—tell you before booking an infusion.
ResearchCompare a six-week runner study with a 28-day study in older adults before treating an NAD claim as a performance promise.
ResearchA controlled trial tested glucose handling directly and found no improvement.
ResearchA muscle-biopsy study puts a popular cellular-energy claim to a direct human test.
ResearchBrain NAD measurements supported further investigation, not a proven disease-modifying treatment.
ResearchA four-week Parkinson’s trial illustrates both the value and limits of early safety research.
ResearchThe NICE trial measured a functional outcome over six months in a defined vascular-disease population.
ResearchA 60-person trial found a null primary test alongside favorable secondary findings.
ResearchA six-week trial found a change in sputum IL-8; the result is narrower than a breathing or longevity claim.
ResearchA 30-person trial examined tolerability and NAD biology in stable heart failure.
ResearchHigher NAD coexisted with no significant advantage in cognition, fatigue, sleep or mood.
ResearchA 42-person trial of MIB-626 separated biochemical response from acute disease outcomes.
ResearchLower liver-enzyme measurements did not establish a reduction in liver fat.
ResearchA small hospital experiment evaluated short exposure and blood NAD, not kidney recovery.
ResearchA 36-person trial found no significant between-group difference in pulse wave velocity.
ResearchPlacebo groups also improved in a 108-person study of fatigue and physical function.
ResearchA placebo-controlled safety study has useful findings and a short observation window.
ResearchA controlled NIAGEN study measured sustained changes in whole-blood NAD and tolerability.
ResearchA 13-person study found selected changes without broad improvement in metabolic function.
ResearchA glucose-challenge study tested pancreatic and gut-hormone responses in men with obesity.
ResearchA 21-day crossover trial distinguishes tissue exposure from improved mitochondrial performance.
ResearchAn early ten-person study examined metabolism and immediate tolerability, not repeated-use benefits.
ResearchA trial in adults aged 60–80 measured blood NAD without isolating the ingredients.
ResearchAn open-label study reported an insulin-related observation in only three participants.
ResearchAn 80-person study reported functional signals without establishing age reversal or an optimal personal dose.
ResearchA ten-week study raised blood NAD while cognitive measures remained stable.
ResearchAn eight-week active-treatment trial found no significant cognitive advantage despite a tau-marker signal.
ResearchA 30-person trial tracked NAD and related compounds over twelve weeks.
ResearchFive months of supplementation changed muscle measurements without improving overall metabolic health.
ResearchForty-two completers provided twelve-week data on cognition and cerebral blood flow.
ResearchAn influential early paper combined human pharmacology with animal comparisons.
ResearchA small open-label study tracked circulating NR and NAD after an escalating research regimen.
ResearchNominal improvements need context from the participant flow and unchanged body composition.
ResearchA crossover trial measured exercise directly rather than assuming a benefit from mitochondrial markers.
ResearchA pilot tested whether NR improved on the same supervised exercise program with placebo.
ResearchA disease-focused niacin study cannot be repackaged as evidence for general NR or NMN wellness use.
ResearchA high-risk skin-cancer trial illustrates the importance of the exact vitamin B3 form and population.